Simplify Testing of Elemental Impurities in Pharmaceuticals with Agilent’s Certified Reference Materials Kit

Significance of the Topic

Elemental impurities in pharmaceuticals pose health risks and must be controlled to meet regulatory limits. The ICH Q3D and USP <232>/<233> guidelines define strict Permissible Daily Exposure (PDE) values by route of administration, replacing older colorimetric heavy-metal tests with modern ICP-based methods. Reliable reference materials accelerate compliance and reduce analytical variability.

Study Objectives and Overview

This application note describes Agilent’s certified reference material (CRM) kits designed for quantifying elemental impurities in oral and parenteral drug formulations. It outlines kit composition, compliance with ICH Q3D/USP <233>, and advantages over in-house standard preparation.

Methodology

Agilent CRMs support compendial testing workflows, featuring:

• Mandated analytes grouped by ICH/USP class and permissible exposure levels.
• Pre-mixed multi-element solutions eliminating manual blending of single-element standards.
• Optimized concentration ranges suitable for both ICP-OES and ICP-MS calibration curves.

Used Instrumentation

• Agilent ICP-MS systems for trace-level detection and quantification.
• Agilent ICP-OES instruments for mid-range elemental analysis.

Key Results and Discussion

Agilent’s CRM kits provide certified concentrations traceable to NIST and include uncertainty data on the Certificate of Analysis. The study highlights:

• Reproducible calibration across multiple kit lots.
• Reduced preparation time compared with single-element stock solutions.
• Minimal analyst error due to pre-formulated standards aligned with PDE levels.

Benefits and Practical Applications

Implementing these CRM kits in quality-control laboratories yields:

• Streamlined workflows for oral and parenteral impurity testing.
• Improved data consistency across different labs and instruments.
• Assured compliance with ICH Q3D/USP <233> without extensive method development.

Future Trends and Opportunities

Anticipated developments include:

• Broader CRM panels covering inhalation and other administration routes.
• Integration with automated sample preparation and data-handling software.
• Extended traceability and uncertainty improvements through enhanced accreditation standards.

Conclusion

Agilent’s ICH Q3D/USP <233> impurity CRM kits simplify elemental analysis in pharmaceuticals by providing ready-to-use, certified standards. They support both ICP-OES and ICP-MS methods, ensure regulatory compliance, and enhance laboratory efficiency.

References

No additional literature references were provided in the source document.